

Supporting Information:

Nicotinic Acid Adenine Dinucleotide Phosphate Analogs Containing Substituted Nicotinic Acid: Effect of Modification on Ca^{2+} Release

Pooja Jain^{§‡}, James T. Slama^{§*}, LeRoy A. Perez-Haddock[†] and Timothy F. Walseth[†]

[§]Department of Medicinal and Biological Chemistry, College of Pharmacy, The University of Toledo, Toledo, OH 43614; [†]Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455

Table of Contents	S1-S4
Figure S1. Scatter plot of log IC ₅₀ vs log EC ₅₀ for NAADP and its' analogs	S5
Figure S2. HPLC analysis of NAADP and analogs 16 – 24	S6
Spectroscopic properties of synthetic compounds	
A. <i>Pyridine-3-carboxylic acids</i>	S7
Figure S3. ¹ H-NMR of 2c : 4- <i>n</i> -butylnicotinic acid	S7
Figure S4. ¹ H-NMR of 2d : 4-phenylnicotinic acid	S8
Figure S5. ¹ H-NMR of 3e : 5-ethynynicotinic acid	S9
Figure S6. ¹³ C-NMR of 3e : 5-ethynynicotinic acid	S10
Figure S7. ¹ H-NMR of 3f : 5-ethenynicotinic acid	S11
Figure S8. ¹³ C-NMR of 3f : 5-ethenynicotinic acid	S12
Figure S9. ¹ H-NMR of 3g : 5-ethylnicotinic acid	S13
Figure S10. ¹³ C-NMR of 3g : 5-ethylnicotinic acid	S14

Figure S11. $^1\text{H-NMR}$ of 3h : 5-phenylnicotinic acid	S15
Figure S12. $^{13}\text{C-NMR}$ of 3h : 5-phenylnicotinic acid	S16
Figure S13. $^1\text{H-NMR}$ of 3i : 5-azidonicotinic acid	S17
Figure S14. $^{13}\text{C-NMR}$ of 3i : 5-azidonicotinic acid	S18
Figure S15. $^1\text{H-NMR}$ of 3j : 5-(4-(aminomethyl)-1 <i>H</i> -1,2,3,-triazol-1-yl)nicotinic acid	S19
<i>B. Synthetic intermediates and products.</i>	
Figure S16. $^1\text{H-NMR}$ of 4 : 3-bromo-5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine	S20
Figure S17 $^1\text{H-NMR}$ of 5 : 1,2-bis(5-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-pyridin-3-yl)ethyne	S21
Figure S18 $^{13}\text{C-NMR}$ of 5 : 1,2-bis(5-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-pyridin-3-yl)ethyne	S22
Figure S19 $^1\text{H-NMR}$: 4- <i>n</i> -butyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine	S23
Figure S20 $^1\text{H-NMR}$: 4-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine	S24
Figure S21 $^1\text{H-NMR}$ of 6 : 4,4-dimethyl-2-(5-((triethylsilyl)ethynyl)pyridine-3-yl)-4,5-dihydrooxazole	S25
Figure S22 $^{13}\text{C-NMR}$ of 6 : 4,4-dimethyl-2-(5-((triethylsilyl)ethynyl)pyridine-3-yl)-4,5-dihydrooxazole	S26
Figure S23 $^1\text{H-NMR}$: 5-ethynyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine; precursor of 5-ethynylnicotinic acid (3e).	S27
Figure S24 $^{13}\text{C-NMR}$: 5-ethynyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine; precursor of 5-ethynylnicotinic acid (3e).	S28
Figure S25 $^1\text{H-NMR}$ of 8 : pinacol ester of 5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-3-pyridinyl boronic	S29

acid (pinacol ester 8)

Figure S26	$^1\text{H-NMR}$ of 9:	5-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine	S30
Figure S27	$^{13}\text{C-NMR}$ of 9:	5-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine	S31
Figure S28	$^1\text{H-NMR}$ of 10:	5-aminonicotinic acid ethyl ester	S32
Figure S29	$^{13}\text{C-NMR}$ of 10:	5-aminonicotinic acid ethyl ester	S33
Figure S30	$^1\text{H-NMR}$ of 11:	5-azidonicotinic acid ethyl ester	S34
Figure S31	$^{13}\text{C-NMR}$ of 11:	5-azidonicotinic acid ethyl ester	S35
Figure S32	$^1\text{H-NMR}$ of 14:	ethyl 5-(4-(aminomethyl)-1 <i>H</i> -1,2,3-triazol-1-yl)nicotinate	S36
Figure S33	$^{13}\text{C-NMR}$ of 14:	ethyl 5-(4-(aminomethyl)-1 <i>H</i> -1,2,3-triazol-1-yl)nicotinate	S37
Figure S34	$^1\text{H-NMR}:$	4-aminonicotinic acid methyl ester	S38
Figure S35	$^{13}\text{C-NMR}:$	4-aminonicotinic acid methyl ester	S39

C. Pyridine dinucleotides

Figure S36.	$^1\text{H-NMR}$ of 15: 4-aminonicotinic acid methyl ester adenine dinucleotide phosphate	S40
Figure S37.	$^{31}\text{P-NMR}$ of 2c: 4-aminonicotinic acid methyl ester adenine dinucleotide phosphate	S41
Figure S38.	$^1\text{H-NMR}$ of 16: 4-amino-NAADP	S42
Figure S39.	$^{31}\text{P-NMR}$ of 16: 4-amino-NAADP	S43
Figure S40.	$^1\text{H-NMR}$ of 17: 4-methyl-NAADP	S44
Figure S41.	$^{31}\text{P-NMR}$ of 17: 4-methyl-NAADP	S45
Figure S42.	$^1\text{H-NMR}$ of 18: 4- <i>n</i> -butyl-NAADP	S46
Figure S43.	$^1\text{H-NMR}$ of 19: 4-phenyl-NAADP	S47

Figure S44. ^{31}P -NMR of 19 : 4-phenyl-NAADP	S48
Figure S45. ^1H -NMR of 20 : 5-amino-NAADP	S49
Figure S46. ^{31}P -NMR of 20 : 5-amino-NAADP	S50
Figure S47. ^1H -NMR of 21 : 5-methyl-NAADP	S51
Figure S48. ^{31}P -NMR of 21 : 5-methyl-NAADP	S52
Figure S49. ^1H -NMR of 22 : 5-carboxy-NAADP	S53
Figure S50. ^{31}P -NMR of 22 : 5-carboxy-NAADP	S54
Figure S51. ^1H -NMR of 23 : 5-ethyl-NAADP	S55
Figure S52. ^{31}P -NMR of 23 : 5-ethyl-NAADP	S56
Figure S53. ^1H -NMR of 24 : 5-azido-NAADP	S57
Figure S54. ^{31}P -NMR of 24 : 5-azido-NAADP	S58
References	S59

IC₅₀ verses EC₅₀ for individual compounds




Figure S1. Scatter plot of the IC₅₀ values derived from competition ligand binding (Table 4)(Y-axis) verses the EC₅₀ values derived from Ca²⁺ release (Table 3)(X-axis).




Figure S2. HPLC of NAADP and its analogs **16 – 24**. Compounds were examined using high pressure liquid chromatography (HPLC) on a 4.6×50 mm column packed with AG MP-1 macroporous anion exchange resin (BioRad Laboratories) with the chromatography developed at 1 mL/min using a mobile phase of 0 – 75 mM trifluoroacetic acid in water¹ immediately prior to testing.

Figure S3. ^1H -NMR (400 mHz, CD_3OD) 4-*n*-butylnicotinic acid




Figure S4. ^1H -NMR (400 mHz, CDCl_3) 4-phenylnicotinic acid.




Figure S5. ^1H -NMR (400 MHz, CD_3OD) 5-ethynylnicotinic acid (**3e**).




Figure S6. ^{13}C -NMR (CD_3OD) 5-ethynynicotinic acid (**3e**).




Figure S7. ^1H -NMR of **3f**: 5-ethenylnicotinic acid




Figure S8. ^{13}C -NMR of **3f**: 5-ethenylnicotinic acid




Figure S9. ^1H -NMR of **3g**: 5-ethylnicotinic acid




Figure S10. ^{13}C -NMR of **3g**: 5-ethylnicotinic acid




Figure S11. ^1H -NMR of **3h**: 5-phenylnicotinic acid



Figure S12. ^{13}C -NMR of **3h**: 5-phenylnicotinic acid




Figure S13. ^1H -NMR of **3i**: 5-azidonicotinic acid




Figure S14. ^{13}C -NMR of **3i**: 5-azidonicotinic acid




Figure S15. ^1H -NMR of **3j**: 5-(4-(aminomethyl)-1*H*-1,2,3,-triazol-1-yl)nicotinic acid




Figure S16. ^1H -NMR of **4**: 3-bromo-5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine




Figure S17 ^1H -NMR of **5**: 1,2-bis(5-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-pyridin-3-yl)ethyne




Figure S18 ^{13}C -NMR of **5**: 1,2-bis(5-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-pyridin-3-yl)ethyne




Figure S19 ^1H -NMR: 4-*n*-butyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine




Figure S20 ^1H -NMR: 4-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine




Figure S21 ^1H -NMR of **6**: 4,4-dimethyl-2-(5-((triethylsilyl)ethynyl)pyridine-3-yl)-4,5-dihydrooxazole




Figure S22 ^{13}C -NMR of **6**: 4,4-dimethyl-2-((triethylsilyl)ethynyl)pyridine-3-yl)-4,5-dihydrooxazole




Figure S23 ^1H -NMR: 5-ethynyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine; precursor of 5-ethynylnicotinic acid (**3e**).




Figure S24 ^{13}C -NMR: 5-ethynyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine; precursor of 5-ethynylnicotinic acid (**3e**).




Figure S25 ^1H -NMR of **8**: pinacol ester of 5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-3-pyridinyl boronic acid (pinacol ester **8**)




Figure S26 ^1H -NMR of **9**: 5-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine




Figure S27 ^{13}C -NMR of **9**: 5-phenyl-3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-pyridine




Figure S28 ^1H -NMR of **10**: 5-aminonicotinic acid ethyl ester




Figure S29 ^{13}C -NMR of **10**: 5-aminonicotinic acid ethyl ester




Figure S30 ^1H -NMR of **11**: 5-azidonicotinic acid ethyl ester




Figure S31 ^{13}C -NMR of **11**: 5-azidonicotinic acid ethyl ester




Figure S32 ^1H -NMR of **14**: ethyl 5-(4-(aminomethyl)-1*H*-1,2,3-triazol-1-yl)nicotinate




Figure S33 ^{13}C -NMR of **14**: ethyl 5-(4-(aminomethyl)-1*H*-1,2,3-triazol-1-yl)nicotinate




Figure S34 ^1H -NMR: 4-aminonicotinic acid methyl ester




Figure S35 ^{13}C -NMR: 4-aminonicotinic acid methyl ester




Figure S36. ^1H -NMR of **15**: 4-aminonicotinic acid methyl ester adenine dinucleotide phosphate




Figure S37. ^{31}P -NMR of **2c**: 4-aminonicotinic acid methyl ester adenine dinucleotide phosphate




Figure S38. ^1H -NMR of **16**: 4-amino-NAADP




Figure S39. ^{31}P -NMR of **16**: 4-amino-NAADP




Figure S40. ^1H -NMR of **17**: 4-methyl-NAADP




Figure S41. ^{31}P -NMR of **17**: 4-methyl-NAADP




Figure S42. ^1H -NMR of **18**: 4-*n*-butyl-NAADP




Figure S43. ^1H -NMR of **19**: 4-phenyl-NAADP




Figure S44. ^{31}P -NMR of **19**: 4-phenyl-NAADP




Figure S45. ^1H -NMR of **20**: 5-amino-NAADP




Figure S46. ^{31}P -NMR of **20**: 5-amino-NAADP




Figure S47. ^1H -NMR of **21**: 5-methyl-NAADP




Figure S48. ^{31}P -NMR of **21**: 5-methyl-NAADP




Figure S49. ^1H -NMR of **22**: 5-carboxy-NAADP




Figure S50. ^{31}P -NMR of **22**: 5-carboxy-NAADP




Figure S51. ^1H -NMR of **23**: 5-ethyl-NAADP




Figure S52. ^{31}P -NMR of **23**: 5-ethyl-NAADP




Figure S53. ^1H -NMR of **24**: 5-azido-NAADP





Figure S54. ^{31}P -NMR of **24**: 5-azido-NAADP



References

- (1) Axelson, J. T.; Bodley, J. W.; Walseth, T. F. A volatile liquid chromatography system for nucleotides. *Anal. Biochem.* **1981**, *116*, 357-360.